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Summary
Combined treatment with trypsin, cholesterol esterase, and neuraminidase transforms LDL, but
not HDL or VLDL, to particles with properties akin to those of lipid extracted from athero-
sclerotic lesions. Single or double enzyme modifications, or treatment with phospholipase C,
or simple vortexing are ineffective . Triple enzyme treatment disrupts the ordered and uniform
structure of LDL particles, and gives rise to the formation ofinhomogeneous lipid droplets 10-
200 nm in diameter with a pronounced net negative charge, but lacking significant amounts of
oxidized lipid. Enzymatically modified LDL (E-LDL), but not oxidatively modified LDL (ox-
LDL), is endowed with potent complement-activating capacity. As previously found for lipid
isolated from atherosclerotic lesions, complement activation occurs to completion via the alter-
native pathway and is independent of antibody. E-LDL is rapidly taken up by human macro-
phages to an extent exceeding the uptake of acetylated LDL (ac-LDL) or oxidatively modified
LDL. After 16 h, cholesteryl oleate ester formation induced by E-LDL (50 N,g/ml cholesterol)
was in the range of 6-10 nmol/mg protein compared with 3-6 nmol/mg induced by an equiv-
alent amount of acetylated LDL. At this concentration, E-LDL was essentially devoid of direct
cytotoxic effects. Competition experiments indicated that uptake of E-LDL was mediated in
part by ox-LDL receptor(s). Thus, -90% of ' 251-ox-LDL degradation was inhibited by a 20-
fold excess ofunlabeled E-LDL. Uptake of 1251-LDL was not inhibited by E-LDL. We hypoth-
esize that extracellular enzymatic modification may represent an important step linking suben-
dothelial deposition of LDL to the initiation of atherosclerosis.
here is wide consensus that subendothelial deposition
oflow density lipoproteins (LDL)' represents the start-
ing point in atherogenesis (1-7) . Accumulation of this lipo-
protein is followed by emigration of blood monocytes to
the affected sites, by their uptake of lipidwith the develop-
ment of foam cells, and by the initiation of a chronic in-
flammatory response that may be sustained by locally re-
leased cytokines in conjunction with immunopathological
cellular events (8, 9). The detrimental processes may possi-
bly be aggravated by local infections (10). Proliferation and
death of fibroblasts, smooth muscle cells, and macrophages,
'Abbreviations used in this paper: ac-LDL, acetylated LDL; E-LDL, enzy-
matically modified LDL; LCA, lesion complement activator; LDH, lactate
dehydrogenase; LDL, low density lipoprotein; MDA, malondialdehyde;
NHS, normal human serum; ox-LDL, oxidatively modified LDL;
TBARS, thiobarbituric acid-reactive substances.
together with enhanced production of extracellular matrix
material, cause thickening of the arterial wall and narrow-
ing ofthe vessel lumen.
Studies conducted in many laboratories have led to a
veritable explosion ofknowledge relating to the fundamen-
tal problem of why LDL, but not other plasma lipopro-
teins, should be endowed with atherogenic potential. Two
intriguing questions are of central interest. First, why are
blood monocytes induced to emigrate to sites of LDL de-
position? Second, why is cellular uptake of deposited LDL
so efficient despite the fact that macrophages express only
low numbers of LDL receptors in normal individuals; and,
macrophage foam cell formation also occurs in individuals
lacking the LDL receptor altogether.
A major advance came with the discoveries that LDL can
be modified in vitro by oxidation (11-14) or acetylation
(15), or by treatment with malondialdehyde (MDA) (16) to
yield molecules with potentially atherogenic properties (17,
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dothelial cells to express adhesive molecules for monocytes,
thus inducing their trams-endothelial passage in vitro (19-
21) . Modified lipoproteins are recognized by scavenger re-
ceptors on macrophages and are rapidly endocytosed (15,
17) . In contrast to uptake of LDL, cholesterol uptake by
the scavenger receptor(s) is not subject to negative feedback
regulation, so that uncontrolled endocytosis will occur
(15) . Transformation of macrophages to foam cells in situ
has, by inference, been widely thought to derive also from
uptake of oxidized or chemically modified LDL via the
macrophage scavenger receptor.
Characterization of lipids present in and extracted from
atherosclerotic lesions has been another area of intense re-
search. Due to the different methods used for their isola-
tion, the lipid preparations examined in different laborato-
ries may be heterogeneous. However, several general
conclusions are probably valid, and they raise problems re-
garding the general validity of the concept that oxidatively
modified LDL is the major instigator ofatherogenesis. First,
the content of oxidized lipid or MDA-LDL in lipids ex-
tracted from the lesions is, at best, minor (22) . Second, le-
sion-derived lipid particles consist mainly of very large
droplets (23-26); this morphology thus differs fundamen-
tally from that of LDL, or ox-LDL, or MDA-LDL. Previ-
ous studies have provided evidence that formation of these
large lipidic particles occurs extracellularly at an early stage
of atherogenesis through fusion of LDL particles (25) .
Third, lesion-derived lipid particles have an unusually high
content of free cholesterol (23, 24, 26-29), and this may be
the reason why they potently activate the alternative com-
plement pathway (29). Finally, lesion-derived lipid particles
are rapidly taken up by macrophages and they thus emerge
as candidates alternative to oxidized or MDA-modified
LDL for evoking foam cell formation (22, 30).
The discovery of a pathway other than oxidation leading
to transformation of LDL to a molecule displaying proper-
ties akin to those of lesion-derived lipids might obviously
help to provide a more plausible working hypothesis on the
pathogenesis of atherosclerosis. We reasoned that enzymes
may play an important role. Tissue proteases could degrade
the lipoprotein B "shell" (31), rendering underlying lipids
accessible to cholesterol esterase . Release of fatty acids
would increase the relative content of free cholesterol, and
neuraminidase could remove an important complement in-
hibitor (32) from the particles. While our studies were un-
der way, one paper appeared showing that combined treat-
ment ofLDL with trypsin and cholesterol esterase provokes
fusion of LDL particles, increases their content of free cho-
lesterol, and that such particles adhere avidly to extracellu-
lar matrix (33) . We will now show that the triple enzyme
combination transforms LDL, but not high density LDL
(HDL) or very low density lipoproteins (VLDL) to particles
endowed with potent complement-activating properties,
and that this enzymatically modified LDL (E-LDL) also
rapidly induces foam cell formation in human macrophages.
Uptake appears to occur in part via the scavenger receptor.
E-LDL thus exhibits similar properties as lesion-derived
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lipid particles, and we hypothesize that it could represent a
major trigger ofatherosclerosis.
Materials and Methods
Native human LDL, HDL, and VLDL were isolated from
pooled human plasma according to conventional procedures (34) .
During the preparation plasma and LDL were kept under N2 and
further protected against artificial oxidation with 500 nmol/liter
EDTA. Lesion complement activator (LCA) was isolated from
atherosclerotic plaques as previously described (29). The choles-
terol contents of the preparations were determined enzymatically
using the cholesterol monotest determination kit from Boeh-
ringer-Mannheim, Mannheim, Germany.
Radioiodination ofLDL.
￿
LDL
￿
was
￿
radioiodinated
￿
using
1,3,4,6-tetrachloro3,6-diphenylglycoluril (35) (lodogen; Sigma
Chemical Co., Deisenhofen, Germany) . 1 ml ofan LDL solution
(5 mg/ml cholesterol) in PBS was adjusted to pH 9.5 with 0.3 M
borate buffer (pH 10.5) and incubated with 0.75 inCi 1251 (Amer-
sham, Braunschweig, Germany) in lodogen-coated plastic caps
(25 Ntg lodogen/cap) for 2 X 5 min. Labeling was terminated
with 2 mM Nal and 2 mM Na2SO3. To remove free " 251, iodi-
nated LDL was passed over a PD-10 Sephadex G25 column
(Pharmacia-LKB, Uppsala, Sweden) . Incorporation of 1251 was
determined by TCA-precipitation oflabeled protein and the spe-
cific activity oflabeled LDL was in the order of 200 cpm/ng cho-
lesterol.
Chemical Modification ofLDL.
￿
For acetylation, LDL solutions
were diluted 1:1 with a saturated Na-acetate solution and placed
on ice. 1 1t1 acetic anhydride/mg LDL-cholesterol was added ev-
ery 15 min for 1 h under gentle shaking, followed by overnight
dialysis against 150 mM NaCI, 5 mM Tris, 1 mM EDTA (15).
Oxidative modification of LDL was achieved as previously de-
scribed (36) with slight modifications. Briefly, LDL solutions
were dialyzed at 4°C overnight against EDTA-free buffer, and
then diluted with Ham's F-10 medium (Flow Laboratories, Irv-
ine, UK) to yield final concentrations of 0.5 mg/ml cholesterol,
and incubated with 50 ILM CUS04 (16 h, 37°C, 5% CO,). Using
this protocol, thiobarbituric acid-reactive substances (TBARS)
were found to be in the range of 60 nM/mg cholesterol. Modi-
fied LDL preparations were stored at 4°C and used within 2 wk.
Measurements of TBARS were performed as described (37).
Samples (0.5 ml) were mixed with 1 ml thiobarbituric acid
(TBA)-solution (0.67% TBA, 0.05 M NaOH, 1 mM EDTA), 0.3
ml TCA (50%), and incubated at 95°C for 30 min in glass tubes.
The samples were cooled to room temperature, mixed with 1 ml
butanol, and centrifuged for 15 min at 2,000 g. The upper phase
was removed and TBARS were determined spectrophotometri-
cally at 532 min in an Ultraspec 11 spectrometer (Phannacia-LKB)
using 1 .1 .3.3.tetraethoxypropane as a standard.
Hydroperoxides in LDL preparations were determined by HPLC
or iodometry (38, 39) . Briefly, 100-1.tl samples were incubated
with 1 ml color reagent (No. 14106; E . Merck AG, Darmstadt,
Germany) for 60 min at room temperature in the dark. Absor-
bance was determined at 365 nm in an Ultraspec 11 spectrometer
using H202 as a standard.
Enzymatic LDL Modifications.
￿
LDL solutions in PBS were ad-
justed to a cholesterol concentration of5 mg/ml. To 0.1 ml LDL
solution were added 0.8 N,l of trypsin stock solution (Sigma
Chemical Co.) (1 mg/ml) and 3 1n,l cholesterol-esterase (Boeh-
ringer-Mannheim) (2 mg/ml). After incubation for 2 h at 37°C in
a Thermomixer (Eppendorf, Hamburg, Germany; 600 rpm), the
pH ofthe solution was adjusted to approximately pH 5 .5 by addi-
tion of 0.1 ml morpholino ethane sulfonic acid (MES) buffer (50mM, pH 4.9), and 1.9 p,l Mg ascorbate (30 mg/ml) and 20 N.1
neuraminidase (Behringwerke, Marburg, Germany) (1 U/ml)
were added. Incubations were continued for 14 h at 37°C.
Thereafter, samples were diluted to 1 ml with MEM (Sigma
Chemical Co.), pH 7.4, so that final concentration of cholesterol
was 0.5 mg/ml. E-LDL was stored at 4°C. E-LDL preparations
that were used in the degradation experiments additionally received
10 pglml (final concentration) aprotinin (Sigma Chemical Co.).
Monocyte Isolation.
￿
Monocytes were isolated from citrated buffy
coats, which were kindly provided by theBlood Transfusion Cen-
ter of the University ofMainz. Monocytes were isolated accord-
ing to Denholm and Wolber (40). Monocyte cell suspensions
regularly contained 70-90% monocytes as determined by flow
cytometry. They were adjusted with MEM + 10% human AB
serum to densities of 1.3-1 .5 X 106 cells/ml. In esterification ex-
periments, 1-ml aliquots ofcell suspensions were applied perwell
to 24-well cell culture plates (Nunc AS, Roskilde, Denmark). In
degradation experiments, 96-well plates (Nunc AS) were used
and each well was seeded with 0.2 ml ofthe cell suspensions. The
cells were cultured for 7 d at 37°C, 5% C02, and medium, sup-
plemented with 10%AB serum, was renewed every 2 d.
Determinations of Cholesteryl Oleate Formation in Macrophages.
0.1 ml of a 500-nM [3H]oleic acid solution with an activity of
2.2 X 107 cpm/ml was added together with 0.9 ml of freshMEM
medium (without serum) containing the respective LDLprepara-
tion to cells, and incubations were performed at 37°C, 5% CO,.
Thereafter, the cells were washed twice with 0.5 ml MEM. Lip-
ids were extracted by 30-min incubations with a 3:2 N-hexane-
isopropanol solution, followed by two further extractions with
this solvent. Lipids were dried under vacuum, taken up in a 2:1
(vol/vol) chloroform/methanol solution, and applied to TLC
plates (Silicagel-TLC-DC-plates ; Machery & Nagel, Diiren, Ger-
many). Chromatographies were performed in hexan-diethyl ether
and acetic acid (83:16:1) and lipid standards (Sigma Chemical
Co.) were run in parallel. The lipid standards were reacted with
8-anilin-l-naphtalene-sulfonic acid solution (Sigma Chemical
Co.) and visualized under a UV lamp. The cholesteryl oleate
band was retrieved, admixed with 10 ml scintillator, and radioac-
tivity determined in a beta counter (LS 6000 TA; Beckman In-
struments, Frankfurt, Germany) . Calibrations were performed by
chromatography of50 li.l and 100 p,l ofthe oleic acid stock solu-
tion. Cholesteryl oleate formation was expressed in picomoles
oleate per milligramcell protein (41) .
For determination ofcell protein, samples were incubated with
0.5 ml of 0.2 N NaOH. Protein determinations were performed
usingthe Bradford reagent (Bio-Rad Laboratories, Munich, Ger-
many) with human albumin as a standard. Direct fluorescent
staining of intracellular lipids was performed by incubating cells
with 10 liM Nile red solution as described (42) .
Degradation Assays.
￿
Degradation assays were performed es-
sentially as described previously (12, 43). In brief, after 5 h of in-
cubation of cells with the respective LDL preparations, cells were
chilled on ice and media were removed. The plates were then
washed and cellular ATP was measured. 1211-labeled degradation
products were determined in the supernatants (0.2 ml samples) by
adding 10 jL,l buffer containing 20% BSA and 0.1 ml of 20%
TCA. After centrifugation, 0.1 ml silver nitrate (5%) was addedto
the supernatant to precipitate free 1211 . Noniodine, TCA-soluble
radioactivity in the supernatant was then determined in a Cobra
Auto Counter (model 5005 ; Packard Instrument Co., Meriden,
CT). To correct for degradation products produced during the
preparation, control incubations were performedin cell-free plates
andthevalues were subtracted from the experimental values .
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Other Determinations.
￿
Cellular ATP levels were determined
using a commercial test kit (No. 567736;Boehringer-Mannheim)
according to the manufacturer's protocol. Briefly, the cells were
lysed with 1% Triton X-100, mixed with the luciferase reagent,
and bioluminescence was determined in a Biolumat LB 9500
(Berthold Laboratories, Wildbad, Germany).
LDH release into the culture medium was measured as follows.
50 p,l of cell supernatant was mixed with 1 nil of a test buffer
containing 0.2 mM NADH, 5 mM EDTA, 50 mM triethanola-
mine-HCI, pH 7.6. Reaction was started by addition ofpyruvate
to 2 mM. Lactate dehydrogenase (LDH) activity was determined
as the decrease ofOD366/ 10 min. Maximum release was determined
in medium of cells lysed with 0.1% Triton X-100. Spontaneous
release from untreated cellswas always <3% of maximal release.
Determination of Complement Activation.
￿
Normal human serum
was prepared from freshly drawn blood of healthy individuals.
Blood was allowed to clot for 30 min at 4°C and subsequently
centrifuged at 2,000gfor 10 min. Serum was used either directly
or given 10 mM EGTA, 2 mM MgCl2, to inhibit classical path-
way activation. Inhibition ofthe classical pathway by EGTA was
ascertained by demonstrating total absence of hemolytic activity
of EGTA-normal human serum (NHS) on antibody-laden sheep
erythrocytes. Preservation of alternative pathway activity was as-
certained by showing that EGTA-NHS could still lyse rabbit
erythrocytes. NHS or EGTA-NHS was incubated with 1 vol li-
poprotein solution and incubated at 37°C in a thermomixer un-
der continuous shaking (500 rpm/min) for 2 h. Reactions were
stopped by adding 10 mM EDTA. For maximum C3 conversion
and maximum generation of SC5b-9, serum samples diluted with
1 vol of MEM were activatedwith particulate inulin (Merck) for
2 h at 37°C. Inulin particles were subsequently removed by cen-
trifugation.
Conversion of C3 was assessed by two-dimensional immuno-
electrophoresis as described (44) . Briefly, 6 [LI of samples was ap-
plied to
￿
/o agarose gels in 0.1 M glycine, 0.038 M Tris, pH 8.7,
and alb
￿
in stained with bromphenol blue was allowed to mi-
grate 4-5 cm (applied voltage: 10 V/cm). Second dimension im-
munoelectrophoresis was performed using anti-C3c (Dakopatts
Immunoglobulins, Copenhagen, Denmark) incorporated into the
gel at a final concentration of 1.2 WI/cm2. Second-dimension im-
munoelectrophoresis was performed overnight at 2 V/cm at
room temperature. Gel plates were pressed, washed, and stained
with Coomassie blue accordingto conventional procedures.
Formation of terminal complement complexes SC5b-9 was
determined by ELISA as previously described with the following
modifications (45) . Instead of thebiotinylated anti-rabbit Ig from
donkey (Amersham International, Little Chalfont, UK) and the
streptavidin-biotinylated peroxidase complex (Amersham Inter-
national), aperoxidase-conjugated anti-rabbit Ig from swine (Da-
kopatts Immunoglobulins) diluted 1:1,000 was applied as the re-
vealing antibody. Absorbance was read at 492 nm in an Easy
Reader (EAR 400; SLT Instruments, Grailsheim, Germany).
Agarose GelElectrophoresis ofLDL.
￿
Agarose gel electrophore-
sis was performed using a commercially available kit (Lipidophor;
Immuno AG, Vienna, Austria). Immune precipitation ofapolipo-
protein B-100 was done with an anti-apo B rabbit anti-human
antibody (Beckman Instruments, Irvine, CA) essentially as de-
scribed by Armstrong et al. (46) . Gels were dried and immune
precipitates were stained using Coomassie blue. Coomassie bril-
liant blue R was obtained from Sigma Chemical Co., St. Louis,
MO, and was dissolved (0.2% wt/vol) in 30% isopropanol/10%
acetic acid/60% water. Slides were stained for 15 min followed
by destaining of the background using the solvent mentionedabove lacking the Coomassie stain . After washing thoroughly
with water, slides were dried at room temperature .
Quantitative rocket immunoelectrophoresis was performed as
described previously (29) . Polyclonal rabbit antibodies against apo
B used in these experiments were obtained from Dakopatts Im-
munoglobulins .
Electron Microscopy .
￿
Preparations of native and E-LDL were
applied as drops to electron microscope grids carrying thin car-
bon-coated Formvar films, made hydrophilic by glow discharge
shortly before use . Adsorbed particles were negatively stained
with 2% sodium silicotungstate as described (47) . The specimens
were examined in a electron microscope (100 CX ; JEOL, Stock-
holm, Sweden) equipped with a high resolution objective lens
pole piece (spherical abberation coefficient, C s 0 .7 mm) and op-
erated at 80 kV . Images were recorded by a low dose exposure
technique on Agfa Scientia 23D56 plates (Agfa, Leunkusen, Ger-
many) developed to an electron speed of 0.7 p,m 2e- . Magnifica-
tion was calibrated using a Fullam S'OZ grating replica No . 6002
(Fullam Inc ., Schenectady, NY) .
Results
Enzymatic Transformation ofLDL to a Complement Activa-
tor. The capacity to activate the alternative complement
pathway was a remarkable feature of lipid isolated from
atherosclerotic lesions (29) . It seemed to us probable that
the LCA was derived from plasma lipoproteins, so we
commenced our present investigations by attempting to
generate a complement-activating lipid from these moi-
eties . All attempts to enzymatically transform HDL and
VLDL to complement activators failed . In contrast, LDL
acquired complement-activating capacity after sequential
treatment with trypsin, cholesterol esterase, and neuramini-
dase . Assays for C3 conversion and SC5b-9 formation were
conducted in 50% NHS and in 50% NHS + 10 mM
EGTA/2 mM MgC1, . Similar results were obtained in
both systems . The classical pathway was ascertained to be
totally inhibited in EGTA/MgC'Z , and the results thus
showed activation to proceed via the alternative pathway .
A panel oftwo-dimensional immunoelectrophoreses show-
ing C3 conversions in 50% NHS is depicted in Fig . 1 . Inu-
lin-activated serum was run as a positive, and the enzyme
cocktail incubated with serum was included as a negative
control . The effects ofox-LDL or native LDL on C3-turn-
over were investigated in parallel . Incubation of serum
with neither the enzyme cocktail nor with ox-LDL or LDL
led to significant C3 conversion . Maximal C3 conversion
occurred in inulin-activated serum . When E-LDL was
added, marked C3-conversion was always observed . By
planimetry, we estimated that E-LDL added at a final con-
centration of 0.4 mg cholesterol/ml to 50% serum pro-
voked over 75% of C3 conversion in 2 h at 37°C . These
results were obtained without exception with 10 different
E-LDL preparations . Complement activation also occurred
in serum that was depleted by >95% of IgG by a passage
over protein G-Sepharose at 0°C . Hence, activation oc-
curred via the alternative pathway and was not due to for-
mation ofimmune complexes . Marked C3 conversion was
never observed ifLDL was modified with a single or any
double enzyme combination .
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Figure 1 .
￿
Analyses of C3-conversion in human serum by crossed im-
munoelectrophoresis . An equivalent of3 I.1 serum was electrophoresed in
each plate . First-dimension electrophoresis was from right to left; the aga-
rose plates contained 1 .2 N,1/cmz of polyclonal rabbit antibodies against
C3 . Control serum exhibited the typical pattern, with a major native C3
precipitate and only small amounts ofC3 cleavage products . Addition of
native LDL or ox-LDL or the enzyme cocktail to serum did not induce
any marked alteration in the electrophoresis pattern. Addition of inulin
(inulin-activated serum : IAS) led to almost complete conversion of C3 ;
addition of E-LDL also led to marked conversion of C3 .
The complement cascade does not inevitably proceed
beyond the stage ofC3 conversion . Cleavage ofC5 is bio-
logically of central importance because this generates the
chemoattractant C5a . We therefore assessed activation of
the terminal complement sequence by quantifying SC5b-9
complexes . Fig. 2 A shows the results of experiments con-
ducted with NHS and EGTA-NHS spiked with E-LDL or
LDL at 0.4 mg cholesterol/ml . Serum activated with inulin
and containing maximal levels of SC5b-9 (^200 jig/nil)
served as positive control . Native LDL or LDL modified
with single or double enzyme treatments, or the enzyme
cocktail alone provoked little generation ofSC5b-9 . How-
ever, LDL treated with the triple enzyme combination was
an effective generator ofSC5b-9 in the presence or absence
ofEGTA . ox-LDL was ineffective (not shown) .
In a further experiment, E-LDL was added at increasing
final concentrations of cholesterol to NHS, and the close-
response curve ofSC5b-9 formation shown in Fig . 2 B was
obtained . Significant activation of the terminal sequence
was detected at E-LDL cholesterol concentrations of%200
jig/nil . This dose-response was comparable to that previ-
ously observed with cholesterol lipid isolated from athero-
sclerotic lesions (29) .
Properties of Enzymatically Modified LDL.
￿
E-LDL
￿
con-
tained no oxidized lipids, as revealed by determination of
lipid hydroperoxides and TBARS . The concentration of
hydroperoxides was below the level ofdetection in samples
of E-LDL and the enzyme cocktail . One preparation of
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Figure 2 .
￿
(A) Detennination ofSC5b-9 inhuman serum by ELISA . Serum samples were incubated with buffer (controo, LDL, the enzyme cocktail, or
E-LDL in the presence (open bars) or absence (closed bars) of 10 MM EGTA/2 rum MgCl2 for 2 h, 37°C . The final concentration of LDL and E-LDL
added was 0 .4 mg/ml cholesterol . Only E-LDL generated large amounts ofSC5b-9, and activation occurred via the alternative complement pathway (n
= 3, ± SD) . (B) Dose-response curve of SC5b-9 generation in human serum induced by E-LDL. E-LDL was added to human serum at the given final
concentrations ofcholesterol and SC5b-9 was measured after 2 h, 37°C. Significant SC5b-9 generation was observed at 200 p,g cholesterol/ml ofE-LDL
(n = 3, ±SD) .
ox-LDL used as a positive control had a hydroperoxide con-
centration of 25 nmol/mg cholesterol in a parallel determi-
nation . Determination ofTBARS with the spectrophoto-
metric method yielded low absorbances with E-LDL that
were identical with background values obtained with the
enzyme cocktail . With the same method, TBARS of 60
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0
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nmol/mg cholesterol were measured in a preparation of
oxidized LDL . Furthermore, no conjugated dienes could
be detected in E-LDL preparations usingHPLC . In this re-
gard, E-LDL thus also appeared similar to LCA . The rela-
tive charge density ofE-LDL was assessed in comparison to
LDL and ox-LDL by agarose gel electrophoresis. As shown
Figure 3 .
￿
Immunoelectrophoresis ofLDL, E-LDL, ac-LDL, and ox-LDL developed with antibodies against apolipoprotein B . First-dimension electro-
phoresis was from right to left, and nativeLDL was applied as control in each plate (lower precipitate ofeach pair) . (A) LDL after 48 h incubation in
buffer, 37°C ; (B) CUS0 4-oxidized LDL; (C) acetylated LDL ; (D) E-LDL . E-LDL was observed to exhibit a strong net negative charge sinular to ac-LDL
and ox-LDL . The weaker precipitate generated by E-LDL was interpreted to reflect loss of epitopes in the molecule .by immune electrophoresis (Fig . 3), E-LDL exhibited a
strong negative charge similar to acetylated LDL (ac-LDL)
and ox-LDL . The total amount of antigen applied in each
analysis was identical, and the weaker precipitate observed
with E-LDL indicated an overall reduction in epitopes. In
fact, prolonged degradation (3-7 d) with the enzyme cock-
tail caused total disappearance ofthe precipitate (not shown) .
In our previous work, we also found that LCA was not
precipitable with antibodies against apo B (29) .
ox-LDL has been reported to exert direct cytotoxic ef-
fects (48), and it was important for our further studies to
determine whether E-LDL was also cytotoxic . Macro-
phages were incubated with E-LDL, and LDH release to
the supernatant as well as cellular ATP levels were mea-
sured after 5 and 16 h . It was found thatE-LDL exerted lit-
tle direct cytotoxic effects when applied at -_50 N ,g/ml
cholesterol . Some cytotoxicity was noted at higher concen-
trations . We also observed that cytotoxicity increased if
E-LDL was stored for days at 4°C . The cause for this was
not investigated, but stored E-LDL was not used in these
1964
degradation experiments (see below) where cytotoxicity
might have generated artifacts .
By electron microscopy, we observed that single enzyme
treatments induced no significant change in LDL micro-
morphology . Treatment with phospholipase C or simple
vortexing were also without gross effect. Treatment with
trypsin + cholesterol esterase did provoke some fusion of
LDL particles . Treatment with a triple enzyme combina-
tion always provoked complete disruption of the uniform
LDL structure and reorganization of lipids into inhomoge-
neous droplets of 10-200 nm in diameter (Fig . 4) . The
morphology of these droplets showed clear resemblance to
that of the LCA described previously (29), and to that of
lipid droplets isolated in other laboratories, particularly by
Kruth et al . (49) . Their dimensions also corresponded to
lipid partices detected in situ by deep-freeze etch electron
microscopy (25) .
Rapid Uptake ofEnzymatically Modified LDL and LCA by
Human Macrophages . The next experiments were under-
taken to determine whether E-LDL and LCA would in-
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Figure 4 . Electron micrographs
of negatively stained preparations
of E-LDL (A) and native LDL (B) .
The triple enzyme treatment
caused disruption of the uniform
LDL particle structure and led to
formation of an inhomogenous
population of lipid particles rang-
ing from 10 to 200 nm in diameter
(the largest particles not shown in
this micrograph) . A number of the
particles exhibited a central stain
deposit indicating a hollow core .
Bars, 100 nm .duce foam cell formation in human macrophages. As a
measure for cholesterol uptake, we quantified the forma-
tion of cholesteryl oleate as described by Brown and Gold-
stein (41) . When freshly isolated monocytes were incu-
bated with E-LDL or LCA, enhanced formation of
cholesteryl oleate was noted, but absolute values of choles-
teryl ester formation were low. Typically, overnight incu-
bation of monocytes with LDL and E-LDL with 50 NLg/ml
cholesterol resulted in formation of 200-400 pmol choles-
teryl oleate/mg protein and 600-800 pmol cholesteryl ole-
ate/mg protein, respectively; cholesteryl oleate formation
induced by LCA was in the same range as found for E-LDL
(data not shown in detail). Incubation with ox-LDL or ac-
LDL resulted in formation of 800-1,000 pmol cholesteryl
oleate/mg protein. The situation was different when cul-
tured human macrophages were used. In these cases, we
noted a dramatic uptake of E-LDL (n = 10) or LCA (n =
3) . LDL treated with single or double enzyme combina-
tions did not markedly promote cholesteryl oleate forma-
tion. When offered to macrophages at 100 la,g/ml choles-
terol, LDL provoked formation of <600 pmol cholesteryl
oleate/mg protein, ac-LDL and LCA induced 3,000-6,000
pmol cholesteryl oleate/mg protein, and incubation with
E-LDL led to formation of >6,000 pmol cholesteryl ole-
ate/mg protein. Fig. 5 A depicts the collective results of six
independent experiments with E-LDL and two experiments
with LCA, wherein the lipoproteins were incubated at 100
Rg/ml cholesterol with human macrophages for 16 h, and
cholesteryl oleate formation was expressed as a percentage
of that observed with ac-LDL. The latter was set at 100%
for each set of determinations. It can be seen that E-LDL
was even more effective in promoting cholesteryl oleate
formation than ac-LDL. Values found for ox-LDL were in
turn always lower than for ac-LDL (not shown) . A dose-
response curve for cholesteryl oleate formation induced by
E-LDL is shown in Fig. 5 B. Cholesteryl oleate formation
LDL AcLDL E-LDL LCA
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virtually plateaued at cholesterol concentrations of 25-50
Rg/ml. An essentially similar dose-response pattern was
originally found by Goldstein et al. in their studies of cho-
lesterol uptake via ac-LDL in mouse macrophages (15).
The results of an experiment to assess the kinetics of
cholesteryl oleate formation are shown in Fig. 6. Choles-
teryl oleate formation provoked by E-LDL or LCA (not
shown) displayed essentially the same kinetics as observed
with acetylated LDL or ox-LDL, commencing at ^"2 h and
continuing over 16 h. These results with ac-LDL and hu-
man macrophages shown here are similar to those origi-
nally reported for mouse macrophages.
In additional experiments intracellular lipids were stained
with Nile red (42) and cells examined by fluorescence mi-
croscopy. Foam cell formation by E-LDL was directly evi-
dent (Fig. 7) .
To obtain an indication whether uptake of E-LDL oc-
curred via a scavenger receptor-dependent pathway, com-
petition experiments were performed in which LDL degra-
dation was measured. We used radioiodinated, ox-LDL,
ac-LDL, or native LDL as ligands and measured apo B deg-
radation in the presence or absence of unlabeled competi-
tors . E-LDL was freshly prepared to avoid cytotoxic effects.
This protocol yielded reproducible results, whereas em-
ployment of radioiodinated E-LDL was impossible because
of unacceptably high backgrounds generated by enzyme
treatment of LDL.
As shown in Fig. 8 A, E-LDL, but not native LDL, ef-
fectively inhibited degradation of 125I-ox-LDL. Control
experiments using the homologous ligand showed 90% in-
hibition by 50 [Lg cholesterol/ml ox-LDL, when 5 N,g
cholesterol/ml of 1251-ox-LDL was offered as substrate.
E-LDL also clearly inhibited ox-LDL uptake and degrada-
tion, albeit to a less effective extent. 25 jig cholesterol/ml
E-LDL inhibited degradation of 1251-ox-LDL by -35%,
and 50 ~t,g/ml E-LDL effected -75% inhibition. Since the
jig Cholesterol/ml
Figure 5.
￿
(A) Measurements of cholesteryl-oleate formation inhuman macrophages. Cells were incubated with LDL, ac-LDL, E-LDL, or LCA at a fi-
nal cholesterol concentration of 50 Wg/ml for 16 h in the presence of [3H]oleate. Thereafter, cell-associated cholesteryl oleate was quantified. The
amount ofcholesteryl oleate determined in cells that had been incubated with ac-LDL was set at 100%, and the relative amounts of cholesteryl oleate
found in the other samples were related to this value. Both LCA (n = 3) and E-LDL (n = 10) induced marked cholesteryl oleate formation (values are
shown --SD). (B) Dose-response curve ofcholesteryl oleate formation in human macrophages induced by E-LDL, ac-LDL, and LDL (n = 4, -_SD) .soon ,
a s s io tz 14 is
Time (h)
Figure 6 .
￿
Kinetics of cholesteryl oleate formation induced in human
macrophages by ac-LDL and E-LDL, each added at final cholesterol con-
centration of 10 ltg/ml. Values are mean ±SD of duplicate determina-
tions ofa representative experiment .
latter concentration was essentially devoid of direct cyto-
toxic effects, the observed inhibition was considered a con-
sequence ofcompetition byE-LDL for the scavenger recep-
tor. The reduced efficiency of E-LDL to inhibit ox-LDL
uptake may partly have been due to the altered physical
properties resulting from aggregation and fusion of the en-
zymatically altered LDL particles .
When either IISI-ac-LDL or "51-LDL was offered as
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ligand (5 pg cholesterol/ml), it was found that E-LDL did
not significantly inhibit degradation (Fig. 8, B and Q,
whereas competition with the respective homologous
ligand occurred as expected . These findings were inter-
preted to indicate that E-LDL uptake occurred at least par-
tially via a scavenger receptor pathway that was specific for
ox-LDL .
Discussion
The results ofthis study show that human LDL, but not
HDL or VLDL, can be altered by treatment with an en-
zyme combination to yield a lipid with atherogenic poten-
tial and with properties akin to those previously reported
for lipids extracted from atherosclerotic lesions . The en-
zymes required for effecting this transition are widely dis-
tributed in microsomal cellular compartments . Similar to all
other investigations reporting methods for creating fused
LDL particles in vitro, the present work does not provide
direct evidence for the presence ofthe modifying agents in
vessel walls . This task is fraught with difficulties and we are
therefore confined to making a hypothesis at the present
stage . Should enzymatic modification ofLDL occur in the
Figure 7 .
￿
Fluorescent staining of intracellular lipid with Nile red. Human macrophages were incubated with buffer (A), LDL (B), ac-LDL (C), or
E-LDL (D) at a final cholesterol concentration of50 ltg/ml for 16 h. Staining with Nile red revealed the marked accumulation ofintracellular lipid in
cells that had been incubated with ac-LDL and E-LDL (X 100) .A
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subendothelium, a simple concept for the initiation of ath-
erosclerosis emerges. Deposition and subendothelial accu-
mulation ofLDL is the first and essential step. This is aggra-
vated by high plasma LDL levels combined with various
factors that promote transendothelial insudation of the li-
poprotein (50). Oxidation of LDL may play a contributing
role, since ox-LDL could locally activate and damage the
endothelium, promoting lipoprotein extravasation and re-
lease of microsomal enzymes (17, 48) . In the subendothe-
lium, apo B is degraded by proteases; this is known to ren-
der cholesterol esters accessible to the action ofcholesterol
esterase (33). The double enzyme modification promotes
first fusions of LDL particles. These particles adhere avidly
to extracellular matrix (33), and their fate to remain en-
trapped in the vessel wall is thus sealed. As sialic acid is re-
moved, further fusions occur and the particles acquire the
capacity to activate the alternative complement pathway.
Activation occurs to completion with the generation of
C5a and is probably due to the high content offree choles-
terol in the particles. Activation is independent of IgG or
formation of immune complexes. C5a that is generated may
represent an important chemotactic stimulus serving to at-
tract monocytes to the lesions. These cells differentiate within
days to macrophages expressing high numbers ofscavenger
receptors. Uptake of E-LDL occurs at least in part via the
scavenger receptor pathway, evoking foam cell formation
and triggering cellular reactions that together propagate
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Figure 8.
￿
Evidence that E-LDL uptake is mediated at least in part via scavenger receptors. (A) Human macrophages were incubated with 1251-ox-LDL
(5 lag cholesterol/ml) in the presence ofthe depicted cold competitors, and degradation of the radiolabeled ligand was detemuned after 5 h. Ox-LDL and
E-LDL inhibited degradation ofradioiodinated ox-LDL, whereas LDL did not (n = 3, ± SD). (B) In the converse experiment, radioiodinated LDL (5 jig
cholesterol/ml) was offered as ligand. In this case, the degradation of LDL could not be significantly inhibited through the addition of E-LDL (n = 3,
±SD). (C When 1251-ac-LDL was used as the ligand, E-LDL also did not effectively inhibit uptake and degradation (n = 2, ±SD).
progression of the inflammatory lesion. As is evident from
the reported experiments, these processes would be ex-
pected to occur in tissues in the presence of the modifying
enzymes. It may be stressed that all experiments described
herein were performed with human LDL and human mac-
rophages.
The hypothesis detracts attention away from the hitherto
dominating concept of oxidative LDL modification being
the key process triggering atherogenesis. We do not con-
tend that oxidation is irrelevant; but propose that enzy-
matic modification may be yet more widespread and possi-
bly represent an essential feature in the pathogenetic
process. As demonstrated by Steinbrecher and Longheed
(22), lipids extracted from atherosclerotic lesions contain
little oxidized fatty acids or MDA-modified LDL. LDL
modified enzymatically in vitro also contains little oxidized
lipids; thus, oxidation is not essential for transformation of
LDL to an atherogenic particle. E-LDL possesses one po-
tentially important property that ox-LDL does not, i.e., the
capacity to spontaneously activate complement and gener-
ate C5a. This is in itself a remarkable finding, and it is the
first and only known example for the transformation of a
plasma component to a complement activator. Of note,
neither HDL nor VLDL exhibit this capacity.
Three important points warrant discussion here. First,
E-LDL particles fuse to form large lipidic particles. Beauti-
ful ultrastructural studies by Frank and Fogelman have pro-vided persuasive evidence that subendothelially deposited
LDL particles actually do fuse together at an early stage of
atherosclerosis; this process occurs extracellularly and pre-
cedes the influx of monocytes and foam cell formation
(25). In their experiments, rabbits were fed a cholesterol-
rich diet and first subendothelial deposition and fusion of
LDL particles were observed after 10 d. In vitro, neither
oxidative modification nor modification with MDA pro-
vokes similar fusion ofLDL particles. Therefore, enzymatic
modification emerges as the most probable candidate for
effecting this morphological transition in vivo . Attention is
here drawn to several earlier studies that described the pres-
ence of such abnormally large lipid droplets in atheroscle-
rotic lesions. The first reports came from the work of
Kruth et al. in 1984 (23, 24), and were followed by work
of Simionescu (26, 51) . In 1990, we purified large lipidic
particles from atherosclerotic plaques and demonstrated their
capacity to activate the alternative pathway (29) . In 1992,
Steinbrecher and Longheed showed that LDL-derived,
large lipid particles isolated from plaques provoked foam
cell formation (22).
The second point relates to the complement-activating
capacity of E-LDL. First studies on the presence of acti-
vated complement in atherosclerotic lesions appeared in
1985 (52), yet the possible participation of complement in
the pathogenesis of atherosclerosis has remained largely ig-
nored. In 1990, we isolated terminal C5b-9 complexes from
human atherosclerotic plaques and thus provided conclusive
evidence that complement activation does occur in the le-
sions. That formation ofthe lipidic LCA occurs extracellu-
larly rather than intracellularly (as a secondary step after
lipid ingestion by macrophages) was originally deduced
from the finding that complement deposition occurred in
animal experiments at a very early stage, paralleling lipid
accumulation but clearly preceding infiltration by mono-
cytes (53) . Our present studies show that LDL can be rap-
idly transformed to a complement activator in vitro in the
absence of cells and thus strengthens this contention. It is
further noteworthy that the described enzymatic treatment
also markedly altered the precipitating properties of LDL;
prolonged treatment led to loss of precipitability. In this re-
gard also, E-LDL thus behaves similarly to LCA, which
was previously found not to be precipitated by antibodies
against apo B (29) . The discovery that enzymatic modifica-
tion of LDL creates large lipid particles with properties that
are essentially identical to those previously found for lipid
droplets isolated from atherosclerotic plaques now provides
a most satisfying explanation for several intriguing and hith-
ertofore poorly understood findings in the literature. Com-
plement activation in the early stages of atherogenesis would
inevitably trigger a variety of biologically relevant processes.
Generation of anaphylatoxins is known to provoke inflam-
mation and to attract phagocytes to the afflicted sites. Co-
valent attachment ofC3b to activator particles leads to their
opsonization and phagocytec uptake. In this regard, it will
be of interest to learn whether uptake of E-LDL by mac-
rophages is accelerated or enhanced in the presence of com-
plement. Another aspect relates to the possible biological
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significance of C5b-9 formation. If any attack on innocent
bystander cells occurs, this would trigger an array of sec-
ondary reactions that could further contribute to the pro-
gression of the lesion (54).
The third point relates to the capacity of E-LDL to be
rapidly taken up by macrophages and to transform these to
foam cells. We have found that LCA is also endowed with
this property. In this regard, E-LDL is even more effective
than ox-LDL or ac-LDL. Mechanisms of E-LDL and LCA
uptake remain to be fully elucidated, and it is realized that
the data presented in this first communication are prelimi-
nary. Our attempts to more completely delineate the up-
take mechanisms have been confounded by difficulties in
preparing satisfactory radioiodinated E-LDL (or LCA) trac-
ers. E-LDL and LCA tend to aggregate and adhere nonspe-
cifically to plastic and glass, so that we have not yet been
able to conduct binding studies. Because of particle aggre-
gation, which apparently enhances spontaneous cytotoxic-
ity, we have also not yet undertaken to isolate subpopula-
tions of E-LDL. These shortcomings notwithstanding, we
do have cause to believe that E-LDL uptake proceeds in
part via a scavenger receptor-dependent pathway. This
conclusion is based on the finding that E-LDL applied at
noncytotoxic concentrations inhibited degradation of ox-
LDL, albeit with somewhat lowered efficiency compared
with ox-LDL itself (Fig. 8). In these experiments, oxida-
tively modified LDL was offered as the radiolabeled ligand.
In contrast, E-LDL did not significantly inhibit uptake and
degradation of 1251-ac-LDL. These findings can be accom-
modated within the framework of current knowledge on
scavenger receptors. Thus, there exist at least three different
classes of scavenger receptors (55, 56). The first class,
termed class A by Krieger and Herz (55), binds both ac-
LDL and ox-LDL, and is inhibitable by polyanions . The
second class (class B) comprises CD36 and related mole-
cules . CD36 is present in macrophages and mediates uptake
of ox-LDL that is not inhibitable by ac-LDL (55, 57) . The
existence of this class of receptors was first reported by
Sparrow et al. in 1989 (58), and the identification of CD36
followed in 1993 by Endemann et al. (57) . Polyanions do
not inhibit uptake of lipoproteins by this class of receptors
(55, 56) . In fact, we found that fucoidan did not inhibit up-
take of E-LDL and in this regard, our data may be related
to results of Steinbrecher and Longheed, who made the
same observation with lipids that they had isolated from
atherosclerotic lesions (22). Thus, CD36 or a related class B
scavenger receptor emerges as a possible candidate that me-
diates uptake ofE-LDL. Further studies are required, how-
ever, especially since a third group of perhaps heterogeneous
molecules may also fulfill scavenger receptor functions (55,
56). At this stage, we certainly cannot exclude the possibil-
ity that E-LDL uptake may occur by a pathway additional
to that mediated by known scavenger receptors.
A few other papers have recently dealt with in vitro ex-
tracellular modifications of LDL. Guyton et al. reported
that simple vortexing provoked LDL aggregation (59).
Other properties of vortexed LDL were not mentioned,
but we have not found that such preparations activate com-plement or induce foam cell formation. Suits et al. de-
scribed the aggregation of LDL particles after treatment
with phospholipase C (60) . We detected neither comple-
ment activation nor promotion of cholesterol esterification
by such preparations. The modification most closely ap-
proaching our protocol was the combined trypsin/choles-
terol esterase treatment described by Chao et al. (33).
When enzymatic treatment was performed as described by
these authors, we found LDL aggregation to be minimal;
the modified LDL preparations were not endowed with
marked complement activation capacity and also did not
induce foam cell formation. If the pH was lowered to be-
low 6 in such preparations, fusion of LDL particles was ag-
gravated and complement-activating properties as well as
foam cell induction appeared. Treatment with neuramini-
dase dramatically augmented these properties to yield the
E-LDL described herein. It is of interest that one group of
investigators has been promoting the concept that removal
of sialic acid from LDL renders the molecule more athero-
genic (61) . Our results are quite compatible with this
thought, although our in vitro data indicate that removal of
sialic acid alone is not sufficient to transform LDL into an
atherogenic molecule.
Finally, a most recent paper reported that in vitro lipoly-
sis of hypertriglyceridemic serum also leads to formation of
liposomes that induce foam cell formation in mouse mac-
rophages (62) . These particles may represent VLDL surface
remnants, and they may represent another relevant class of
atherogenic lipids.
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